Friday, July 10, 2026

pharma · Colorectal Neoplasms · Borderline Resectable Pancreatic Adenocarcinoma

Zhejiang Rongyao Biotech

Zhejiang Rongyao Biotech clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
1999 Founded
5 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Founded
1999
Employees
5
Programs
2
Drugs
3
Patents
0
Intelligence · Clinical Programs

Zhejiang Rongyao Biotech projects

2 ClinicalTrials.gov programs sponsored by Zhejiang Rongyao Biotech.

Zhejiang Rongyao Biotech has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Cetuximab β;Fruquintinib;

    Zhejiang University

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial
  2. HRS-4642+AG+Nimotuzumab

    Zhejiang University

    Borderline Resectable Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Zhejiang Rongyao Biotech have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.